Cargando…

Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma

Chk1 is a member of the DNA damage response pathway, whose loss leads to replication stress and genome instability. Because of its protective role against lethal levels of DNA replication stress, Chk1 has been studied as a valuable and intriguing target for cancer therapy. However, one of the most p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Black, Elizabeth M., Joo, Yoon Ki, Kabeche, Lilian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2022
Materias:	Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704517/ https://www.ncbi.nlm.nih.gov/pubmed/36416754 http://dx.doi.org/10.1042/BCJ20220461

Ejemplares similares

Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway
por: Hunter, Jill E., et al.
Publicado: (2022)

Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistance
por: Hunter, Jill E., et al.
Publicado: (2022)

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis
por: Leslie, Jack, et al.
Publicado: (2023)

Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001)

Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cells
por: Hunter, Jill E., et al.
Publicado: (2022)

Chk-mate on resistance to kinase inhibitors
por: Shapiro, Paul
Publicado: (2018)

Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity
por: Massey, Andrew J.
Publicado: (2016)

Mangrove dolabrane‐type of diterpenes tagalsins suppresses tumor growth via ROS‐mediated apoptosis and ATM/ATR–Chk1/Chk2‐regulated cell cycle arrest
por: Neumann, Jennifer, et al.
Publicado: (2015)

Regulation of Chk1
por: Tapia-Alveal, Claudia, et al.
Publicado: (2009)

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
por: Nair, Jayakumar, et al.
Publicado: (2020)

Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation via derepression of Chk1 catalytic activity
por: Walker, M, et al.
Publicado: (2009)

Dominant mutations in CHK1 cause pronuclear fusion failure and zygote arrest that can be rescued by CHK1 inhibitor
por: Zhang, Honghui, et al.
Publicado: (2021)

BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1
por: Li, Lemin, et al.
Publicado: (2023)

The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor
por: Liang, Xiaobing, et al.
Publicado: (2011)

Regulation, targets and functions of CHK
por: Zhu, Shudong, et al.
Publicado: (2022)

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
por: Rawlinson, Rebecca, et al.
Publicado: (2014)

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
por: Manic, Gwenola, et al.
Publicado: (2015)

SALL4 induces radioresistance in nasopharyngeal carcinoma via the ATM/Chk2/p53 pathway
por: Nie, Xin, et al.
Publicado: (2019)

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736
por: Restelli, Valentina, et al.
Publicado: (2015)

Clinical and functional significance of CHK1-S, an alternatively spliced isoform of the CHK1 gene, in hepatocellular carcinoma
por: Hu, Guanghui, et al.
Publicado: (2020)

Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation
por: Yu, Xinfang, et al.
Publicado: (2020)

Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro
por: Wang, Zhihui, et al.
Publicado: (2018)

Analysis of CHK2 in vulval neoplasia
por: Reddy, A, et al.
Publicado: (2002)

Chk1 suppressed cell death
por: Meuth, Mark
Publicado: (2010)

Checkmate to CHK1 in T-cell ALL?
por: Sarmento, Leonor M., et al.
Publicado: (2015)

Editorial: Regulation and dysfunction of CSK and CHK
por: Zhu, Shudong, et al.
Publicado: (2023)

Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma
por: Dai, Bojie, et al.
Publicado: (2011)

CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin
por: Di Franco, Simone, et al.
Publicado: (2021)

A novel Chk1-binding peptide that enhances genotoxic sensitivity through the cellular redistribution of nuclear Chk1
por: Kim, Kwang Seok, et al.
Publicado: (2016)

Targeting Chk1 in the replicative stress response
por: Dai, Yun, et al.
Publicado: (2010)

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
por: Di Benedetto, Anna, et al.
Publicado: (2017)

AR phosphorylation and CHK2 kinase activity regulates IR-stabilized AR–CHK2 interaction and prostate cancer survival
por: Ta, Huy Q, et al.
Publicado: (2020)

Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S‐phase arrest and promoting apoptosis through CHK1 pathway
por: Wu, Fan, et al.
Publicado: (2015)

Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer
por: Liu, Kang, et al.
Publicado: (2021)

The DNA repair component Metnase regulates Chk1 stability
por: Williamson, Elizabeth A, et al.
Publicado: (2014)

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia
por: Di Tullio, Alessandro, et al.
Publicado: (2017)

Chk1 Haploinsufficiency Results in Anemia and Defective Erythropoiesis
por: Boles, Nathan C., et al.
Publicado: (2010)

CHK2 kinase in the DNA damage response and beyond
por: Zannini, Laura, et al.
Publicado: (2014)

Targeting the ATR-CHK1 Axis in Cancer Therapy
por: Rundle, Stuart, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kvi3iol4p6f5e6m4epqpd65s8v